161 related articles for article (PubMed ID: 29144542)
1. Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
Schairer C; Pfeiffer RM; Gadalla SM
Int J Cancer; 2018 Mar; 142(6):1202-1208. PubMed ID: 29144542
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Dunnwald LK; Rossing MA; Li CI
Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
[TBL] [Abstract][Full Text] [Related]
3. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for breast cancer according to estrogen and progesterone receptor status.
Colditz GA; Rosner BA; Chen WY; Holmes MD; Hankinson SE
J Natl Cancer Inst; 2004 Feb; 96(3):218-28. PubMed ID: 14759989
[TBL] [Abstract][Full Text] [Related]
6. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
7. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup.
Cotterchio M; Kreiger N; Theis B; Sloan M; Bahl S
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1053-60. PubMed ID: 14578142
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study.
Gadalla SM; Amr S; Langenberg P; Baumgarten M; Davidson WF; Schairer C; Engels EA; Pfeiffer RM; Goedert JJ
Br J Cancer; 2009 Mar; 100(5):817-21. PubMed ID: 19190628
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
10. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status.
Huang WY; Newman B; Millikan RC; Schell MJ; Hulka BS; Moorman PG
Am J Epidemiol; 2000 Apr; 151(7):703-14. PubMed ID: 10752798
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status.
Marshall SF; Bernstein L; Anton-Culver H; Deapen D; Horn-Ross PL; Mohrenweiser H; Peel D; Pinder R; Purdie DM; Reynolds P; Stram D; West D; Wright WE; Ziogas A; Ross RK
J Natl Cancer Inst; 2005 Jun; 97(11):805-12. PubMed ID: 15928301
[TBL] [Abstract][Full Text] [Related]
12. Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status.
Zhang M; Yang H; Holman CD
Breast Cancer Res Treat; 2009 Dec; 118(3):553-63. PubMed ID: 19252980
[TBL] [Abstract][Full Text] [Related]
13. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults.
McGee EE; Castro FA; Engels EA; Freedman ND; Pfeiffer RM; Nogueira L; Stolzenberg-Solomon R; McGlynn KA; Hemminki K; Koshiol J
Int J Cancer; 2019 Feb; 144(4):707-717. PubMed ID: 30155920
[TBL] [Abstract][Full Text] [Related]
14. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
Suzuki R; Ye W; Rylander-Rudqvist T; Saji S; Colditz GA; Wolk A
J Natl Cancer Inst; 2005 Nov; 97(21):1601-8. PubMed ID: 16264180
[TBL] [Abstract][Full Text] [Related]
15. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
Wei JL; Zhang JX; Fu DY
World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
[TBL] [Abstract][Full Text] [Related]
16. The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States).
Tarone RE; Chu KC
Cancer Causes Control; 2002 Feb; 13(1):7-14. PubMed ID: 11899120
[TBL] [Abstract][Full Text] [Related]
17. Second primary breast cancer occurrence according to hormone receptor status.
Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
[TBL] [Abstract][Full Text] [Related]
18. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.
Li CI; Malone KE; Daling JR
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):601-7. PubMed ID: 12101106
[TBL] [Abstract][Full Text] [Related]
19. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups.
Chu KC; Anderson WF
Breast Cancer Res Treat; 2002 Jun; 74(3):199-211. PubMed ID: 12206512
[TBL] [Abstract][Full Text] [Related]
20. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
